From the Howard Hughes Medical Institute and the
Department of Pharmacology, University of Texas
Southwestern Medical Center, Dallas, Texas 75235-9050
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
A novel membrane form of guanylyl cyclase (GC-G) has been identified through the isolation of a full-length cDNA clone; it is predicted to contain an extracellular ligand binding domain, a single transmembrane segment, and intracellular protein kinase-like and cyclase catalytic domains. That GC-G represents a guanylyl cyclase was confirmed by both transient expression in COS-7 cells and stable expression in H293 cells. Endogenous cyclic GMP concentrations of transfected or stable cells, however, were much higher than control cells, suggesting an inability of the cells to effectively regulate GC-G cyclase activity. Of six Cys residues found within the extracellular domain of guanylyl cyclase-A (GC-A), the receptor for atrial natriuretic peptide, five are conserved within GC-G. Ligands for the other cyclase receptors, nevertheless, failed to stimulate GC-G expressed in transient or stable cells, suggesting that the unknown ligands possess a structure different from the natriuretic peptides or heat-stable enterotoxins. 125I-ANP also failed to bind to H293 cells overexpressing GC-G. Based on Northern hybridization, mRNA for GC-G was predominantly expressed in lung, intestine, and skeletal muscle. Using the candidate gene approach to potentially define function, the gene for GC-G was mapped to the distal region of mouse chromosome 19 (syntenic with human chromosome 10q), but no human genetic defect has been ascribed to the GC-G locus. The finding of a new membrane form of guanylyl cyclase in peripheral tissues suggests the existence of another family or subfamily of ligands that signal through elevations of cGMP.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Of the six membrane forms of guanylyl cyclase in the mammal, three are receptors for known ligands, whereas three remain presumed orphans (1). The first mammalian cyclase cDNA isolated encoded a receptor (guanylyl cyclase-A (GC-A)1) for atrial natriuretic peptide (ANP) (2, 3). Disruption of the GC-A gene yields mice with a salt-resistant form of elevated blood pressure (4), and it has been subsequently suggested that GC-A is the primary means by which the heart communicates with the kidney to cause natriuresis/diuresis when vascular volume is acutely increased by intravenous infusion (5). The guanylyl cyclase-B receptor (GC-B) appears to bind C-type natriuretic peptide (CNP) with highest affinity, and although its normal functions remain unclear (6, 7), it has been suggested to regulate cell growth (8, 9) and blood pressure (10, 11). GC-C represents the receptor for heat-stable enterotoxins (STa) and possibly two endogenous peptides, guanylin and uroguanylin (12-14). It has been suggested to normally regulate intestinal fluid secretion (15), but disruption of the GC-C gene has not resulted in an adverse phenotype when mice are raised in a disease-free environment. In fact, GC-C null mice are resistant to STa- or enterotoxigenic bacteria-induced diarrhea (16). The three orphan guanylyl cyclase receptors are expressed in sensory tissues, two in the retina (17-19) and one in olfactory neuroepithelium (20). GC-D, the olfactory-specific guanylyl cyclase is a marker for an apparently unique subset of olfactory neurons that also express phosphodiesterase type 2 (21). The number of mammalian guanylyl cyclase receptors is not known, but the recent work of Yu et al. (22), showing the existence of 29 or more guanylyl cyclases in Caenorhabditis elegans, many or most of which are expressed in distinct sensory neurons, raises the question of whether a significant number of orphan guanylyl cyclase receptors remain to be identified in the mammal. In 1990, Schulz et al. (12) obtained a PCR product from intestinal cDNA that was unique compared with the known mammalian cyclases described above. Within a short period of time, a partial length clone that included the cyclase catalytic and protein kinase-like domains was obtained from an intestinal cDNA library, but the full-length cDNA clone proved difficult to isolate, possibly due to mRNA secondary structure. Here, the sequence for the full-length cDNA clone is presented. The novel plasma membrane guanylyl cyclase receptor (GC-G) retains Cys residues conserved in the guanylyl cyclase-A receptor but is not activated by natriuretic peptides. The apparent receptor is expressed in highest amounts in lung, intestine, and skeletal muscle where it likely interacts with a unique class or subclass of ligands that signal through cGMP.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cloning of GC-G--
Poly(A)+RNA prepared from small
intestinal mucosa of the rat was reverse transcribed using an oligo(dT)
primer and Superscript reverse transcriptase (Life Technologies, Inc.).
First strand cDNA was used as a template for PCR with degenerate
oligonucleotide primers based on conserved sequences within the
catalytic domains of membrane and cytoplasmic forms of guanylyl cyclase
(23). PCR products were cloned into M13 and sequenced. In addition to several known guanylyl cyclases, a unique sequence was amplified that
was later shown to be GC-G. When the unique PCR product, designated
SIM3, was used to screen a small intestine cDNA library, a clone
corresponding to GC-C, the heat-stable enterotoxin receptor, was
obtained (12). Therefore, the sequence of SIM3 was extended using
3-RACE (24). The sense guanylyl cyclase primer and an oligo(dT)
antisense primer were used in the PCR, and a single product of 550 base
pairs was obtained and sequenced. This PCR product encoded the 3
-end
of GC-G and was subsequently used as a probe to screen the same library
from which GC-C was obtained (12). Two partial length clones were
obtained, both of which contained unspliced introns. Numerous cDNA
libraries constructed in various manners were screened, and the longest
cDNA clone obtained extended no further than about 300 base pairs
5
of the putative transmembrane segment; this is the beginning of exon
6 based on other guanylyl cyclase sequences. A combination of 5
-RACE
and genomic sequence information yielded exons 1-5. Predicted exon 1 was joined to exon 2 by splice overlap PCR and then assembled with
exons 2-5 and the cDNA clone encoding exon 6 through the poly(A)+ tail. The final construct was sequenced.
Northern Blots--
For detection of GC-G mRNA, 5 µg of
poly(A)+ RNA was fractionated on a formaldehyde-1% agarose
gel, then transferred to a nylon membrane. The membrane was probed with
a radioactively labeled cDNA fragment corresponding to the 5-end
of GC-G (a part of the extracellular coding region; see Fig.
6B) or to part of the catalytic domain (see Fig.
6C). Following hybridization overnight at 42 °C, the
membrane was washed at 60 °C in 0.5 × SSC, and mRNA
corresponding to GC-G was visualized by autoradiography for 7 days at
80 °C (see Fig. 6B). For detection of GC-G mRNA in
rat lung, the membrane was washed at 60 °C in 1 × saline/sodium phosphate/EDTA and exposed to a film for 3 days at
80 °C (see Fig. 6C). For detection of mRNA in H293
cells expressing GC-G, 2.5, 4.5, or 7.0 µg of total RNA were
fractionated on a formaldehyde, 1% agarose gel and processed as
described above except for washing conditions. The membrane was washed
for 10 min at 65 °C with 2 × SSC, 0.1% SDS, for 20 min at
65 °C with 0.5 × SSC, 0.1% SDS and for 1 min at room
temperature with 0.1 × SSC. The mRNA corresponding to GC-G
was visualized using a phosphoimager (Fuji Biosystems).
GC-G Expression-- The full-length GC-G cDNA was cloned into the mammalian expression vector pCMV5. For transient transfections, COS-7 cells were grown on 100-mm plates in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B. Cells were transiently transfected using the DEAE-dextran method with 5 µg of plasmid (pCMV5, GC-G/pCMV5, or GC-A/pCMV5) per 100-mm plate. For stable expression, H293 cells were cotransfected with a pCMV5/GC-G construct and a pCMV5 construct containing a oubain-resistance gene using lipofection. H293 cells were grown in Opti-MEM I medium (Life Technologies, Inc.) for the first 24 h, which was then replaced with DMEM supplemented as described for COS-7 cells. For selection of ouabain-resistant clones, 0.5 µM ouabain was included in the medium. After several rounds of amplification, isolated oubain-resistant clones were tested for expression of GC-G by Western blot analysis.
Preparation of Membranes-- COS-7 cells expressing GC-G were harvested 48 h after transfection; GC-G/H293 cells were grown to confluency before harvest. For preparation of membranes, cells were washed twice with 5 ml of ice-cold phosphate-buffered saline and scraped into 1 ml of ice-cold homogenization buffer (10% glycerol, 50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 10 µg/ml leupeptin, 1 µg/ml pepstatin, and 10 µg/ml aprotinin). Cells were disrupted by sonication and centrifuged for 20 min at 2 °C and 100,000 × g. The membrane pellet was washed twice with homogenization buffer, and membranes were resuspended in 1 ml of homogenization buffer by sonication.
Guanylyl Cyclase Assay--
Assays were performed in a total
volume of 100 µl with 25 mM HEPES, pH 7.4, 50 mM NaCl, 0.25 mM IBMX, 0.1% bovine serum
albumin, 10 mM NaN3, 1 mM
dithiothreitol, 100 µM GTP, 0.5 µCi/100 µl assay [-32P]GTP (NEN, 3000 Ci/mmol, 10 mCi/ml), and 5 mM MnCl2 or MgCl2 as well as 0.1%
Triton X-100 as indicated. Reactions were started by the addition of
membrane fraction to the assay mix and tubes were incubated for 10 min
at 37 °C. Reactions were stopped with zinc acetate/sodium carbonate
and radiolabeled [
-32P]cGMP was isolated and
quantified as described in Ref. 25.
Cyclic GMP Formation in Intact Cells-- For determination of cGMP accumulation in COS-7 cells transiently expressing GC-G, 100-mm plates were washed twice with 2 ml of DMEM medium (see above, without additives) and incubated with DMEM containing 0.25 mM IBMX at 37 °C. After 10 min, this medium was exchanged with DMEM containing 0.25 mM IBMX without additives or with 1 µM ANP, 1 µM BNP, 1 µM CNP, or 1 µM STa and incubated for an additional 10 min. The reaction was stopped by addition of 2 ml of 1 N perchloric acid, and cGMP concentrations were estimated as described (25).
125I-ANP Binding-- Membranes from control or GC-G stably expressing H293 cells were prepared as described above. 125I-ANP binding was basically assayed as described previously with the exception that Whatman GF/C filters were used for filtration (26). Membranes were incubated with 200 pM 125I-ANP in the absence or presence of 0.1 µM competing unlabeled ANP for 1 h at room temperature.
Western Blots-- A synthetic peptide corresponding to the carboxyl-terminal decapeptide of GC-G (EEEAKVPEIL) was conjugated to PPD (2,5-diphenyl-1,3,4-oxadiazole, Serumstaaten Institute) using glutaraldehyde. The purified conjugate was used to raise a polyclonal antiserum in rabbits. For Western blotting, 25-50 µg of membrane protein of GC-G expressing COS-7 or H293 cells was separated on 8% sodium dodecyl sulfate-polyacrylamide gels. Proteins were electrophoretically transferred to polyvinylidene fluoride membranes, and nonspecific protein-binding sites of the membranes were blocked by incubation with TBST (Tris-buffered saline with Tween-20: 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween-20) containing 5% non-fat dry milk at room temperature for 1 h or at 4 °C overnight. Membranes were washed with TBST and incubated for 1 h at room temperature in a 1:1,000 dilution of primary antibody. Membranes were washed three times with TBST and then incubated with a 1:10,000 dilution of a horseradish-conjugated anti-rabbit antibody (Bio-Rad) in TBST. After washing the membranes three times with TBST, protein bands were detected using the enhanced chemiluminescence detection method (ECL, Amersham Corp.).
Chromosomal Localization--
The chromosomal location of the
gene encoding GC-G was determined by the use of a DNA panel derived
from 94 progeny of an interspecific backcross (C57BL/6J × Mus spretus) of females with C57BL/6J males (Jackson BSB,
Jackson Lab Backcross DNA Panel Map Service; Ref. 27). A sense primer
(5-TCTCAGAACTCAGAAGGAAAACTGC) in intron 1 (based on the rat genomic
sequence) was used with an antisense primer in exon 2 (5
-ATGCTGGCAGTGATGTTGAAATGGA). A size polymorphism was detected (1 kb
for M. spretus and 1.2 kb for C57BL/6). Backcross progeny
DNA was typed using a standard PCR containing 125 ng of genomic DNA
with 25 pmol of each primer in a total volume of 25 µl. DNA was
denatured in an initial 5-min incubation at 95 °C followed by 5 min
at 72 °C, during which time Taq polymerase was added.
Thermal cycling was for 40 cycles (45 s at 94 °C, 45 s at
60 °C, 2 min at 72 °C) followed by a 20-min incubation at
72 °C. Reaction products were separated on an 0.8% agarose gel with
parental samples for comparison.
![]() |
RESULTS AND DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
GC-G cDNA-- The cDNA and predicted amino acid sequence for GC-G are given in Fig. 1. The open reading frame predicts a protein of 1100 amino acids containing a putative signal peptide of 43 amino acids. GC-G is similar to the other membrane forms of guanylyl cyclase (Fig. 2) in that a single transmembrane domain divides the protein approximately in half, separating an extracellular region from two prominent intracellular domains (protein kinase-like and cyclase catalytic). Of seven cysteine residues within the extracellular domain of GC-G, five align with five of six found in GC-A (Fig. 3). These cysteine residues are also conserved in other guanylyl cyclases (Fig. 3; Ref. 22). The ANP clearance receptor binds natriuretic peptides and contains an extracellular domain whose primary amino acid sequence is 30-40% identical to GC-A or GC-B (2, 3, 6, 28). Recent mapping of the disulfide bonding pattern of this receptor demonstrates that the first two Cys and second two Cys residues (from the amino terminus) form internal disulfide bonds (29, 30). The site of ANP binding has been mapped just to the amino-terminal side of the second disulfide loop (31), suggesting that this region is critical for ligand binding. Limited sequence information from genomic clones of GC-G also demonstrates that intron/exon boundaries are at the same positions in the GC-G gene as in the GC-A and the ANP clearance receptor genes (32, 33). The intron/exon boundaries are different in GC-C and in the sensory guanylyl cyclases (34),2 and thus GC-G appears more closely related evolutionarily to the natriuretic peptide receptors than to other guanylyl cyclases (Fig. 2). A comparison of the extracellular domains of GC-G with the ANP clearance receptor, and a grouping of amino acids according to major chemical properties, shows that the two extracellular domains are more than 40% similar (Fig. 4).
|
|
|
|
Expression of GC-G Activity-- To confirm that GC-G encodes guanylyl cyclase activity and to facilitate searches for a putative ligand, the cDNA was expressed in either COS-7 or H293 cells. Cyclic GMP concentrations in either COS-7 or H293 cells were much higher than that seen when GC-A or GC-B are overproduced in the same cells (2, 35), suggesting that these cells do not effectively regulate GC-G activity (Fig. 5). Guanylyl cyclase activity was estimated in membranes prepared from H293 cells stably expressing GC-G (Fig. 5A). The addition of high concentrations (1 µM) of ANP, BNP, CNP, or STa had little, if any, effect on cell cGMP concentrations in COS-7 cells transiently expressing GC-G (Fig. 5B).
|
Natriuretic Peptide Binding-- Since cGMP concentrations appeared poorly regulated by either COS-7 or H293 cells transfected with GC-G, direct binding assays were designed to determine whether GC-G might bind such a peptide with high affinity but fail to demonstrate regulation.
However, no detectable 125I-ANP binding to the GC-G overproducing cells was detected (data not shown).Tissue Expression of GC-G-- Based on Northern hybridization, mRNA for GC-G is most prominent in lung, intestine, and skeletal muscle (Fig. 6, B and C). Various cell lines have been examined by reverse transcription-PCR and also contain detectable GC-G mRNA (data not shown). Multiple sized mRNAs were observed in the various tissues using a cDNA probe encoding the extracellular domain or the catalytic domain. A cDNA probe to the apparent intracellular region of GC-G also yielded three positive-hybridizing mRNA species (36). However, when the mRNA of H293 cells stably expressing GC-G was examined, only mRNA at the size of the predicted product was detected (Fig. 6A). Therefore, the multiple sized mRNAs in the various tissues likely reflects alternative splicing. That GC-G is in various peripheral tissues raises the possibility that the ligand for GC-G circulates. Its expression in skeletal muscle is particularly provocative since a role for cyclic GMP in muscle has been largely ignored. Conceivably, however, GC-G is a component of the smooth muscle vasculature in skeletal muscle as opposed to skeletal muscle itself. If so, then possibly GC-G stimulation would lead to increased blood flow to the muscle in certain physiological states, such as in response to exercise. Our attempts to identify cells in which GC-G is expressed by in situ hybridization, however, have so far not been successful.
|
Chromosomal Localization-- Based on these analyses, the gene for GC-G (gucy2g) maps to the distal region of mouse chromosome 19 and close to the anchor locus D19Mit1. This region is syntenic with human chromosome 10 q24-26. There do not appear to be genetic diseases in the human that have been mapped to the GC-G locus (Fig. 7).
|
![]() |
ACKNOWLEDGEMENTS |
---|
We extend appreciation to Dr. David Goeddel and members of his research group, in particular Dr. Fred deSauvage, who provided considerable advice during the mid-phases of this work. We are grateful to Lynda Doolittle and Deborah E. Miller for excellent technical assistance. We also thank Lucy R. Rowe and Mary B. Barter (The Jackson Laboratory) for analysis of the BSB panel and advice in preparation of Fig. 7.
![]() |
FOOTNOTES |
---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF024622.
§ Present address: Division of Clinical Pharmacology, Dept. of Medicine, Thomas Jefferson University, 1100 Walnut St., Philadelphia, PA 19107.
¶ Initially supported by a fellowship from Deutsche Forschungsgemeinschaft and to whom correspondence should be addressed: UTSWMC, 5323 Harry Hines Blvd., Dallas, TX 75235-9050. Fax: 214-648-5087; E-mail: bwedel{at}mednet.swmed.edu.
1 The abbreviations used are: GC-A to -G, guanylyl cyclase-A to -G, respectively; ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide, CNP, C-type natriuretic peptide; STa, heat-stable enterotoxin from E. coli; gucy2g; gene for GC-G; RACE, rapid amplification of cDNA ends; PCR, polymerase chain reaction; DMEM, Dulbecco's modified Eagle's medium; IBMX, 3-isobutyl-1-methylxanthine.
2 S. Schulz, unpublished results.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|